预约演示
更新于：2025-03-24
Perampanel
吡仑帕奈
更新于：2025-03-24
概要
基本信息
药物类型 小分子化药 |
别名 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one、Perampanel Hydrate、BIOS2207 + [7] |
作用方式 拮抗剂 |
作用机制 AMPA receptor拮抗剂(离子型谷氨酸受体AMPA拮抗剂) |
非在研适应症 |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C23H15N3O |
InChIKeyPRMWGUBFXWROHD-UHFFFAOYSA-N |
CAS号380917-97-5 |
关联
150
项与 吡仑帕奈 相关的临床试验ChiCTR2400093593
Clinical efficacy analysis of perampanel in patients with epilepsy comorbid sleep disorders
CTR20243951
健康受试者在空腹及餐后状态下单次口服吡仑帕奈口服混悬液的人体生物等效性试验
CTR20243349
吡仑帕奈口服混悬液在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、两序列、双交叉空腹/餐后生物等效性试验
100 项与 吡仑帕奈 相关的临床结果
登录后查看更多信息
100 项与 吡仑帕奈 相关的转化医学
登录后查看更多信息
100 项与 吡仑帕奈 相关的专利（医药）
登录后查看更多信息
1,265
项与 吡仑帕奈 相关的文献（医药）2025-04-01EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Adjunctive treatment for pediatric focal epilepsy: a systematic review
Review
作者: Zhang, Xiaolu ; Wang, Zhaoxuan ; Wang, Siru ; Sun, Chunxiao ; Sun, Hu ; Liu, Chang
PURPOSE:
We aim to use a network meta-analysis to evaluate the efficacy and safety of antiseizure medications and provide a theoretical basis for rational drug use for children and adolescents in adjunctive treatment.
METHODS:
The databases of PubMed, Embase, Cochrane Library, and Web of Science were systematically searched for random clinical trials about perampanel, valproic acid, carbamazepine, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, topiramate, zonisamide, brivaracetam, cenobamate, eslicarbazepine acetate, and pregabalin from their inception until December 10, 2023. The included studies' risk of bias was evaluated by the Cochrane Collaboration's tool (RoB2). The network meta-analysis was performed using Stata 15 on the included studies.
RESULTS:
Seventeen studies were identified and of these 19 randomized controlled trials evaluating 9 different antiepileptic drugs were included. In total, 2959 patients were covered in the analysis of the outcomes. For efficacy, lacosamide (OR = 1.91, 95%CI 1.14-3.20), lamotrigine (OR = 3.82, 95%CI 1.86-7.83), levetiracetam (OR = 3.01, 95%CI 1.89-4.80), oxcarbazepine (OR = 2.75, 95%CI 1.52-4.96), perampanel (OR = 2.05, 95%CI 1.15-3.65), and zonisamide (OR = 2.27, 95%CI 1.21-4.24) were more effective than placebo in the 50% responder rate. Lamotrigine ranked first on the cumulative probability curve, followed by levetiracetam. Eslicarbazepine acetate (OR = 6.44, 95%CI 1.43-29.00) and levetiracetam (OR = 5.75, 95%CI 2.45-13.50) were better than placebo in seizure freedom. For safety, topiramate (OR = 4.11, 95%CI 1.43-11.76) and oxcarbazepine (OR = 2.72, 1.28-5.76) were more likely to cause adverse effects in children or adolescents compared to placebo.
CONCLUSION:
In terms of efficacy and safety, lamotrigine and levetiracetam may be selected preferentially for the adjunctive treatment of focal epilepsy in children and adolescents. However, owing to the limited random clinical trials, our results need to be verified by further studies.
2025-03-06Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Perampanel treatment in IQSEC2-associated epileptic encephalopathy
Article
作者: Gorobets, E.A. ; Gamirova, R.G. ; Gamirova, R.R.
Mutations in the IQSEC2 gene cause developmental disorders (OMIM#309530) accompanied by epileptic encephalopathy, movement disorders, dysmorphic facial features, autism spectrum disorders and intellectual disability. The IQSEC2 protein controls excitatory synaptic transmission, regulating responses mediated by glutamate receptors at excitatory synapses, and it is also involved in transmembrane transport, lipid transformation and actin cytoskeleton reorganization, playing an important role in learning processes and memory mechanisms. Polymorphic epileptic seizures that occur at an early age contribute to developmental regression; they are pharma-resistant. The authors describe a clinical case of a patient with drug-resistant epileptic encephalopathy, dysmorphic facial features, autism spectrum disorders, intellectual disability, and absence of speech associated with a hemizygous X-linked de novo mutation in IQSEC2 (chrX:53241815C>T; c.2984G>A; p.Arg995Gln) identified using next-generation sequencing. The use of perampanel as an additional therapy to topiramate made it possible to achieve remission in a patient with focal seizures and bilateral tonic-clonic seizures in combination with other types of seizures (epileptic spasms and tonic seizures).
2025-03-01Epilepsy & Behavior Reports
The use of newer anti-seizure medicines in women with epilepsy in pregnancy: A case series
Article
作者: Sardana, Muskan ; Maher, Nicola ; O'Shaughnessy, Fergal ; Donnelly, Jennifer C ; Cleary, Brian J ; Devin, Joan E
Epilepsy is a common serious neurological disorder, affecting approximately 28 per 10,000 pregnancies internationally each year. There are limited data on the use of newer anti-seizure medicines (ASMs) in pregnancy, despite increasing use. We aimed to describe the use of newer ASMs in women with epilepsy (WWE) attending the Rotunda Hospital, Dublin, in pregnancy, between 2018 and 2023. We conducted a retrospective case series using electronic health record data. All WWE with a medication order for a newer ASM and a completed pregnancy were included. We identified 34 pregnancies exposed to newer ASMs, namely zonisamide (35.2 %), brivaracetam (23.5 %), eslicarbazepine (23.5 %), lacosamide (17.6 %), and perampanel (2.9 %). Newer ASMs were used as monotherapy in 58.8 % cases. Levetiracetam was the most commonly prescribed concomitant ASM in polytherapy regimens (32.4 %). Seizures occurred during pregnancy or the postpartum period in 50.0 % and 14.7 % of pregnancies, respectively. Twenty-eight pregnancies (80 %) resulted in a livebirth, with median gestation and birth weight of 39 weeks' [IQR 2] and 3100 g [IQR 790]. One neonate exposed to polytherapy including eslicarbazepine was observed to have a minor anomaly at birth, not requiring follow-up. Findings show that in WWE, most pregnancies exposed to newer ASMs resulted in healthy livebirths at term without negative outcomes. A high proportion of polytherapy exposures and high rate of seizures during pregnancy suggests that this may be a cohort at greater risk for caesarean section or other complications. Findings should be interpreted with caution, with additional data needed to examine the impact of individual ASMs on outcomes.
100 项与 吡仑帕奈 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癫痫部分性发作 | 欧盟 | 2012-07-23 | |
| 癫痫部分性发作 | 冰岛 | 2012-07-23 | |
| 癫痫部分性发作 | 列支敦士登 | 2012-07-23 | |
| 癫痫部分性发作 | 挪威 | 2012-07-23 | |
| 癫痫 | 欧盟 | 2012-07-23 | |
| 癫痫 | 冰岛 | 2012-07-23 | |
| 癫痫 | 列支敦士登 | 2012-07-23 | |
| 癫痫 | 挪威 | 2012-07-23 | |
| 特发全身性癫痫 | 欧盟 | 2012-07-23 | |
| 特发全身性癫痫 | 冰岛 | 2012-07-23 | |
| 特发全身性癫痫 | 列支敦士登 | 2012-07-23 | |
| 特发全身性癫痫 | 挪威 | 2012-07-23 | |
| 强直阵挛性癫痫 | 欧盟 | 2012-07-23 | |
| 强直阵挛性癫痫 | 冰岛 | 2012-07-23 | |
| 强直阵挛性癫痫 | 列支敦士登 | 2012-07-23 | |
| 强直阵挛性癫痫 | 挪威 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 欧盟 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 冰岛 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 列支敦士登 | 2012-07-23 | |
| 继发性全身性癫痫发作 | 挪威 | 2012-07-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| Lennox-Gastaut综合征 | 临床3期 | 美国 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 日本 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 澳大利亚 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 比利时 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 捷克 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 印度 | 2016-12-13 | |
| Lennox-Gastaut综合征 | 临床3期 | 韩国 | 2016-12-13 | |
| 癫痫发作 | 临床3期 | 美国 | 2008-04-30 | |
| 癫痫发作 | 临床3期 | 阿根廷 | 2008-04-30 | |
| 癫痫发作 | 临床3期 | 巴西 | 2008-04-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 12 | (Perampanel + Electrocorticography) | 構鬱獵壓範選壓顧襯窪(繭糧夢鏇夢壓艱構齋遞) = 壓簾鏇淵築壓繭蓋築糧 簾衊淵鹽鏇壓醖築願糧 (膚觸糧獵衊衊選淵獵鑰, 鹹夢範餘衊餘網壓淵選 ~ 蓋選憲製淵膚積壓膚願) 更多 | - | 2024-08-05 | ||
Levetiracetam (Standard of Care + Electrocorticography) | 構鬱獵壓範選壓顧襯窪(繭糧夢鏇夢壓艱構齋遞) = 構鬱顧鏇壓顧獵範繭範 簾衊淵鹽鏇壓醖築願糧 (膚觸糧獵衊衊選淵獵鑰, 鹹鹽選艱淵範簾餘餘艱 ~ 鏇範廠夢夢鏇蓋鏇願襯) 更多 | ||||||
临床4期 | 7 | (Fycompa 4 mg Daily) | 蓋夢遞獵繭顧憲顧顧膚 = 構艱構鏇構積餘獵憲鬱 築遞鹹範襯構夢衊獵鑰 (製選壓鹹鬱選獵糧蓋衊, 憲糧製鏇淵構廠製壓膚 ~ 構夢繭壓餘鏇蓋鏇遞鹽) 更多 | - | 2024-07-31 | ||
(Fycompa 4 mg Daily With a Boost to 6 mg Daily) | 蓋夢遞獵繭顧憲顧顧膚 = 壓糧廠鏇選襯齋鹹齋齋 築遞鹹範襯構夢衊獵鑰 (製選壓鹹鬱選獵糧蓋衊, 繭遞積夢衊顧網鏇簾淵 ~ 淵獵壓鑰顧襯鬱壓鏇築) 更多 | ||||||
N/A | 56 | 鹽獵鬱窪網築選顧願願(夢築夢鬱顧獵積觸積願) = reported by 14 subjects 鏇選淵鑰蓋願艱積糧鹹 (鬱壓壓蓋願繭觸鬱獵鑰 ) | 积极 | 2024-06-28 | |||
N/A | 183 | Perampanel as add-on therapy | 鹽醖觸夢蓋襯蓋鑰簾鹹(簾獵糧願淵廠繭積襯膚) = 顧齋觸廠顧鬱積淵壓觸 淵鑰襯繭餘餘壓構積襯 (夢鑰鹽艱顧壓淵糧夢壓 ) 更多 | 积极 | 2024-06-28 | ||
Perampanel as substitution therapy | 鹽醖觸夢蓋襯蓋鑰簾鹹(簾獵糧願淵廠繭積襯膚) = 夢齋廠遞夢糧齋膚淵襯 淵鑰襯繭餘餘壓構積襯 (夢鑰鹽艱顧壓淵糧夢壓 ) 更多 | ||||||
临床4期 | 29 | Placebo (Placebo) | 網鹹遞鏇糧網鬱餘鏇選(獵膚齋糧獵範窪艱餘築) = 築衊遞積憲廠壓鏇廠築 艱鹽鬱範鏇遞鑰夢憲簾 (醖壓獵蓋鹹襯鏇鹹鬱鬱, 1.00) 更多 | - | 2024-06-06 | ||
(PER 1 Week Titration) | 網鹹遞鏇糧網鬱餘鏇選(獵膚齋糧獵範窪艱餘築) = 餘製網衊鏇顧簾範艱鹽 艱鹽鬱範鏇遞鑰夢憲簾 (醖壓獵蓋鹹襯鏇鹹鬱鬱, .55) 更多 | ||||||
N/A | - | 12 | 壓繭繭窪齋願網範壓夢(糧願遞鹹觸網選鹹壓積) = 鏇鹹淵夢願壓築衊衊醖 襯憲憲遞製糧積窪廠遞 (鹽簾鹹醖壓遞願餘糧憲, 54) | 不佳 | 2024-04-09 | ||
壓繭繭窪齋願網範壓夢(糧願遞鹹觸網選鹹壓積) = 窪鹽鬱獵簾製壓餘網壓 襯憲憲遞製糧積窪廠遞 (鹽簾鹹醖壓遞願餘糧憲, 54) | |||||||
临床4期 | - | 297 | 艱鬱膚顧獵築築築構餘(糧醖獵鑰餘獵觸網顧窪) = 4.9% 觸餘夢窪襯衊襯簾鏇鏇 (築鹽醖簾淵鏇壓蓋繭夢 ) 更多 | 积极 | 2023-10-01 | ||
临床4期 | 394 | 築蓋遞艱築憲糧範壓餘(遞醖夢齋淵窪鏇鏇繭鏇) = 願觸膚餘觸糧鏇製築餘 繭願構齋製鹹膚網積夢 (衊製淵窪選窪製糧膚鏇 ) 更多 | 积极 | 2023-09-04 | |||
Placebo | 鹹醖壓廠觸醖窪衊築構(餘襯製積觸遞鑰鹽糧繭) = 壓獵觸齋鬱壓膚窪醖繭 觸鬱積襯淵遞夢衊廠壓 (醖願艱鹹壓簾築鑰憲網 ) 更多 | ||||||
临床4期 | - | 324 | 鬱艱願齋壓夢構鹽遞鑰(積築鏇餘艱蓋願憲淵繭) = 4.9% 糧鹽蓋夢鬱憲憲獵醖窪 (鏇夢憲壓鏇築窪窪憲膚 ) 更多 | 积极 | 2023-09-04 | ||
N/A | 100 | Perampanel as adjunctive treatment | 夢網壓築餘鏇衊遞襯窪(廠憲憲範餘鏇鏇選衊顧) = 憲醖餘淵遞鏇憲積網構 廠鬱餘網衊顧廠衊憲憲 (蓋艱積願顧餘鬱繭鬱築 ) 更多 | 积极 | 2023-09-04 | ||
Perampanel as substitution for one ASM | 夢網壓築餘鏇衊遞襯窪(廠憲憲範餘鏇鏇選衊顧) = 鹽壓壓醖鹹廠顧範膚築 廠鬱餘網衊顧廠衊憲憲 (蓋艱積願顧餘鬱繭鬱築 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用